Cost-effectiveness of disease-modifying therapies for Alzheimer dementia in Ireland

5-state Markov cohort model | HSE payer perspective | HIQA guidelines | Validated against published manuscripts

Sevinc Elif Sen, MSc — Independent health economist, Dublin, Ireland | 2026

Drug

Hazard ratio

0.69

Treatment (months)

Drug cost (EUR/yr)

24,766

Discount rate (%)

4.0%

Include caregiver costs (societal)

ICER (EUR/QALY)

Threshold: EUR 45,000

Incremental cost

Treatment vs SoC

Incremental QALYs

Lifetime horizon

Times threshold

ICER / EUR 45,000

Outcome	Treatment + SoC	SoC alone	Increment

Lecanemab ICER

CLARITY-AD | HR 0.69

Donanemab ICER

TRAILBLAZER-ALZ 2 | HR 0.73

Lecanemab zero-drug

Drug = EUR 0

Donanemab zero-drug

Drug = EUR 0

© 2026 Sevinc Elif Sen, MSc | Independent health economist, Dublin, Ireland | All rights reserved
Full model with PSA (10,000 Monte Carlo), Markov trace, and scenario analyses available for licensing — contact sevincelifalkan@gmail.com

sevinc elif sen | sevincelifalkan@gmail.com